These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 27714433)

  • 1. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
    Ellmark P; Mangsbo SM; Furebring C; Norlén P; Tötterman TH
    Cancer Immunol Immunother; 2017 Jan; 66(1):1-7. PubMed ID: 27714433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
    Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
    Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
    Gerber HP; Sapra P; Loganzo F; May C
    Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies in cancer immunotherapy.
    Chen S; Li J; Li Q; Wang Z
    Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated T cells armed with bispecific antibodies kill tumor targets.
    Bhutani D; Lum LG
    Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
    Herrera-Camacho I; Anaya-Ruiz M; Perez-Santos M; Millán-Pérez Peña L; Bandala C; Landeta G
    Expert Opin Ther Pat; 2019 Aug; 29(8):587-593. PubMed ID: 31241380
    [No Abstract]   [Full Text] [Related]  

  • 8. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
    Yu L; Wang J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspectives of bispecific antibody-based immunotherapy.
    Talac R; Nelson H
    J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies for viral immunotherapy.
    Nyakatura EK; Soare AY; Lai JR
    Hum Vaccin Immunother; 2017 Apr; 13(4):836-842. PubMed ID: 27786606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
    Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
    Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
    Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
    Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of T cells in tumor immunology and immunotherapy].
    Ladányi A
    Magy Onkol; 2019 Sep; 63(3):165-171. PubMed ID: 31533135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.